Medical 21 files Form D for $20 million equity offering

Medical 21, Inc., based in Plymouth, Minnesota, filed a Form D with the Securities and Exchange Commission dated October 22, 2026, disclosing a new exempt securities offering. The total offering amount is listed as $20,000,000, with $550,000 already sold and $19,450,000 remaining to be sold.¹

The filing states the date of first sale as September 17, 2026, and marks the notice as a new filing rather than an amendment.¹ Three investors have already invested in the offering.¹ The company said the offering is not intended to last more than one year.¹

The security type offered is equity, as indicated by the issuer's selection on the form.¹ The company is relying on the Rule 506(b) exemption under Regulation D.¹ The minimum investment accepted from any outside investor is listed as $0.¹

No sales commissions or finder's fees have been paid, with both listed at $0.¹ The company estimates $500,000 of the offering proceeds will go to payments for executive officers, directors, or promoters named in the filing, with the filing noting a portion of proceeds will cover general working capital purposes, including officer salaries.¹

The filing lists four related persons with executive or director roles: Manny Villafana as an executive officer and director, Eric Solien as an executive officer, Jeff Vreeman as an executive officer, and Andrea Sweeney as an executive officer.¹ The notice was signed by Villafana, identified as Chief Executive Officer, on October 22, 2026.¹

The filing classifies the company under the biotechnology industry group within health care, as marked on the form, though it does not provide further description of the company's products or clinical programs.¹ The offering is not being made in connection with a business combination transaction such as a merger or acquisition.¹